Andrew Beck, PathAI CEO and co-founder
GlaxoSmithKline keeps trucking alongside AI with new, multi-year pathology partnership with Boston outfit
Big Pharma has been in hot pursuit of the allure of AI integration, with the alleged potential for revolutionizing drug R&D. The UK’s GlaxoSmithKline has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.